Dixon RA - Search Results

1

Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist.

Wu C, Chan MF, Stavros F, Raju B, Okun I, Mong S, Keller KM, Brock T, Kogan TP, Dixon RA. Wu C, et al. Among authors: dixon ra. J Med Chem. 1997 May 23;40(11):1690-7. doi: 10.1021/jm9700068. J Med Chem. 1997. PMID: 9171878

2

Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist.

Wu C, Decker ER, Blok N, Bui H, You TJ, Wang J, Bourgoyne AR, Knowles V, Berens KL, Holland GW, Brock TA, Dixon RA. Wu C, et al. Among authors: dixon ra. J Med Chem. 2004 Apr 8;47(8):1969-86. doi: 10.1021/jm030528p. J Med Chem. 2004. PMID: 15055997 Clinical Trial.

3

Novel synthetic inhibitors of selectin-mediated cell adhesion: synthesis of 1,6-bis[3-(3-carboxymethylphenyl)-4-(2-alpha-D- mannopyranosyloxy)phenyl]hexane (TBC1269).

Kogan TP, Dupré B, Bui H, McAbee KL, Kassir JM, Scott IL, Hu X, Vanderslice P, Beck PJ, Dixon RA. Kogan TP, et al. Among authors: dixon ra. J Med Chem. 1998 Mar 26;41(7):1099-111. doi: 10.1021/jm9704917. J Med Chem. 1998. PMID: 9544210

4

Endothelin antagonists: substituted mesitylcarboxamides with high potency and selectivity for ET(A) receptors.

Wu C, Decker ER, Blok N, Bui H, Chen Q, Raju B, Bourgoyne AR, Knowles V, Biediger RJ, Market RV, Lin S, Dupré B, Kogan TP, Holland GW, Brock TA, Dixon RA. Wu C, et al. Among authors: dixon ra. J Med Chem. 1999 Nov 4;42(22):4485-99. doi: 10.1021/jm9900063. J Med Chem. 1999. PMID: 10579813

5

Acyl substitution at the ortho position of anilides enhances oral bioavailability of thiophene sulfonamides: TBC3214, an ETA selective endothelin antagonist.

Wu C, Decker ER, Blok N, Li J, Bourgoyne AR, Bui H, Keller KM, Knowles V, Li W, Stavros FD, Holland GW, Brock TA, Dixon RA. Wu C, et al. Among authors: dixon ra. J Med Chem. 2001 Apr 12;44(8):1211-6. doi: 10.1021/jm000349x. J Med Chem. 2001. PMID: 11312921

6

Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.

Tilton RG, Munsch CL, Sherwood SJ, Chen SJ, Chen YF, Wu C, Block N, Dixon RA, Brock TA. Tilton RG, et al. Among authors: dixon ra. Pulm Pharmacol Ther. 2000;13(2):87-97. doi: 10.1006/pupt.2000.0237. Pulm Pharmacol Ther. 2000. PMID: 10799286

7

Nonpeptide endothelin antagonists in clinical development.

Wu C, Decker ER, Holland GW, Brown PM, Stavros FD, Brock TA, Dixon RA. Wu C, et al. Among authors: dixon ra. Drugs Today (Barc). 2001 Jul;37(7):441-453. doi: 10.1358/dot.2001.37.7.844187. Drugs Today (Barc). 2001. PMID: 12750762

8

Recently discovered sulfonamide-, acyl sulfonamide- and carboxylic acid-based endothelin antagonists.

Wu C, Holland GW, Brock TA, Dixon RA. Wu C, et al. Among authors: dixon ra. IDrugs. 2003 Mar;6(3):232-9. IDrugs. 2003. PMID: 12789612 Review.

9

Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension.

Tilton RG, Brock TA, Dixon RA. Tilton RG, et al. Among authors: dixon ra. Expert Opin Investig Drugs. 2001 Jul;10(7):1291-308. doi: 10.1517/13543784.10.7.1291. Expert Opin Investig Drugs. 2001. PMID: 11772252 Review.

10

Growth factor antagonists for the treatment of diabetic vascular complications.

Tilton RG, Dixon RA, Brock TA. Tilton RG, et al. Among authors: dixon ra. Expert Opin Investig Drugs. 1997 Nov;6(11):1671-84. doi: 10.1517/13543784.6.11.1671. Expert Opin Investig Drugs. 1997. PMID: 15989571

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

810 results

Search Page

Filters